Pulmonary Fibrosis News and Research RSS Feed - Pulmonary Fibrosis News and Research

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a very aggressive form of pulmonary fibrosis and has a particularly poor prognosis. This fatal disease, for which so far no causal therapies exist, is characterized by a massive deposition of connective and scar tissue in the lung, which leads to a progressive loss of lung function and ultimately death. [More]
Study stresses importance of investigating telomeres to improve diagnoses, develop treatments for many diseases

Study stresses importance of investigating telomeres to improve diagnoses, develop treatments for many diseases

Studying telomeres, the structures that protect the ends of chromosomes, has become a key issue in biology. In recent years, not only has their relation to ageing been confirmed; defective telomeres seem to be linked to more and more illnesses, including many types of cancer. [More]
Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
Scientists gain insights into dynamic remodeling of tissue during lung repair

Scientists gain insights into dynamic remodeling of tissue during lung repair

Our lungs are permanently exposed to harmful environmental factors that can damage or even destroy their cells. In a specific regenerative process these injured cells must be replaced as soon as possible. In collaboration with colleagues from the Max Planck Institute of Biochemistry, scientists at the Helmholtz Zentrum München have now, for the first time, gained detailed insights into the dynamic remodeling of the tissue during lung repair. [More]
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
Veracyte named to Bay Area News Group's Top Workplaces list for second consecutive year

Veracyte named to Bay Area News Group's Top Workplaces list for second consecutive year

Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has been named to the Bay Area News Group's prestigious Top Workplaces list for the second year in a row. The news group selects Top Workplace winners based solely on an annual survey of Bay Area-company employees. [More]
Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone. [More]
Autoantibodies play major role in IPF patients with acute exacerbations

Autoantibodies play major role in IPF patients with acute exacerbations

Patients with acute exacerbations of idiopathic pulmonary fibrosis responded well to therapies similar to those used to treat autoimmune diseases, according to findings published today in PLOS ONE. The study suggests that autoantibodies — implicated in many autoimmune diseases such as rheumatoid arthritis or lupus — also play an important role in patients with acute exacerbations of IPF, a devastating lung disease. [More]
Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF). [More]
Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures. [More]
Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V., one of the world's leading global pharmaceutical companies. [More]
Triciribine drug may reverse progression of pulmonary fibrosis and pulmonary hypertension

Triciribine drug may reverse progression of pulmonary fibrosis and pulmonary hypertension

Researchers at the University of Georgia have discovered that the drug triciribine may reverse or halt the progression of pulmonary fibrosis and pulmonary hypertension, two respiratory diseases that are almost invariably fatal. [More]
New therapeutic target discovered for idiopathic pulmonary fibrosis

New therapeutic target discovered for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected. [More]
Mutations in PARN and RTEL1 associated with familial pulmonary fibrosis, telomere shortening

Mutations in PARN and RTEL1 associated with familial pulmonary fibrosis, telomere shortening

Researchers at UT Southwestern Medical Center have identified mutations in two genes that cause a fatal lung scarring disease known as familial pulmonary fibrosis. [More]
Scientists test effectiveness of new method for treating COPD

Scientists test effectiveness of new method for treating COPD

Scientists at Helmholtz Zentrum München have succeeded in testing the effectiveness of new approaches for treating chronic obstructive pulmonary disease (COPD) on ex vivo 3D human lung tissue cultures (3D-LTCs). The results have now been published in the European Respiratory Journal. [More]
Latest genome sequencing techniques help identify new autoimmune syndrome in children

Latest genome sequencing techniques help identify new autoimmune syndrome in children

Using the latest genome sequencing techniques, a research team led by scientists from UC San Francisco, Baylor College of Medicine, and Texas Children's Hospital has identified a new autoimmune syndrome characterized by a combination of severe lung disease and arthritis that currently has no therapy. [More]
Veracyte launches new genomic test to improve lung cancer diagnosis

Veracyte launches new genomic test to improve lung cancer diagnosis

Veracyte, Inc., a molecular diagnostic company pioneering the field of molecular cytology, today announced the launch of its Percepta Bronchial Genomic Classifier, a new genomic test to resolve ambiguity in lung cancer diagnosis. The company will soon begin testing patient samples in its CLIA-certified laboratory, with the Percepta test now available to a limited number of institutions around the country. [More]
Veracyte, GE parnter to develop new solutions to improve disease diagnosis

Veracyte, GE parnter to develop new solutions to improve disease diagnosis

Veracyte, Inc., a molecular diagnostic company pioneering the field of molecular cytology, and GE today announced a research collaboration to develop new solutions that can improve disease diagnosis. [More]
New study describes way to regenerate lung tissue after injury

New study describes way to regenerate lung tissue after injury

A new collaborative study describes a way that lung tissue can regenerate after injury. The team found that lung tissue has more dexterity in repairing tissue than once thought. [More]
Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC). [More]
Advertisement
Advertisement